Node Smith, ND

South Australian researchers working with Oracle Cloud technology and vaccine technology, developed by local company Vaxine Pty Ltd., are testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic.

Vaxine testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic

The team is headed by Nikolai Petrovsky, Flinders University Professor and Research Director at Vaxine.

His team has tapped Oracle for technical collaboration, access to an expanded research community, and cloud infrastructure that helped enable the rapid design of the novel COVID-19 vaccine candidate.

“The vaccine has progressed into animal testing in the US and, once we confirm it is safe and effective, will then be advanced into human trials,” says Professor Petrovsky — stressing expectations shouldn’t be elevated until all testing is completed.

Oracle enabled the team to “dramatically speed up ability to analyse the COVID-19 virus”

The latest cloud-based technology provided by Oracle enabled the team to “dramatically speed up our ability to analyse the COVID-19 virus and use this information to design the vaccine candidate.”

COVID-19 genomic sequence used to characterize key viral attachment molecule called spike protein

“As soon as the genomic sequence of COVID-19 became available in January, we immediately used this, combined with our previous experience in developing a SARS coronavirus vaccine, to characterise the key viral attachment molecule called the spike protein,” Professor Petrovsky says.

“We used computer models of the spike protein and its human receptor, ACE2, to identify how the virus was infecting human cells, and then were able to design a vaccine to block this process,” he says.

Flinders University Associate Professor Dimitar Sajkov, a respiratory physician in South Australia, has been involved in conducting previous human trials of the team’s pandemic vaccines and hopes to similarly lead clinical trials of this new COVID-19 vaccine candidate.

“The team has exploited the very latest technologies, including AI, advanced manufacturing and Cloud computing to accelerate vaccine design, shaving years off normal development timeframes,” Professor Sajkov says.

Vaxine’s swine flu vaccine developed during the 2009 swine flu pandemic

“We achieved great results with Vaxine’s swine flu vaccine developed during the 2009 swine flu pandemic, where we commenced clinical trials of a vaccine within 3 months of discovery of the virus. We hope to achieve similar results with their COVID-19 vaccine candidate when it is ready for human testing,” he says.

1. Flinders University. “Vaccine candidate against SARS-CoV-2 being tested.” ScienceDaily. ScienceDaily, 3 April 2020. <www.sciencedaily.com/releases/2020/04/200403103944.htm>

---

Node Smith, ND, is a naturopathic physician in Humboldt, Saskatchewan and associate editor and continuing education director for NDNR. His mission is serving relationships that support the process of transformation, and that ultimately lead to healthier people, businesses and communities. His primary therapeutic tools include counselling, homeopathy, diet and the use of cold water combined with exercise. Node considers health to be a reflection of the relationships a person or a business has with themselves, with God and with those around them. In order to cure disease and to heal, these relationships must be specifically considered. Node has worked intimately with many groups and organizations within the naturopathic profession, and helped found the non-profit, Association for Naturopathic Revitalization (ANR), which works to promote and facilitate experiential education in vitalism.